Results 251 to 260 of about 752,942 (288)
Some of the next articles are maybe not open access.

Proteasome inhibitors for cancer therapy

Bioorganic & Medicinal Chemistry, 2012
Proteasome, a large multicatalytic proteinase complex that plays an important role in processing of proteins, has been shown to possess multiple catalytic activities. Among its various activities, the 'chymotrypsin-like' activity of proteasome has emerged as the focus of drug discovery efforts in cancer therapy. Herein we report chiral boronate derived
Mohamed, Iqbal   +6 more
openaire   +2 more sources

[Proteasome inhibitors].

Nihon rinsho. Japanese journal of clinical medicine, 2010
The 26S proteasome is a multicatalytic enzyme responsible for degradation of a large fraction of intracellular proteins. Targeting the proteasome activity is a rational and novel strategy for cancer therapy that can lead to cell death for transformed cells.
Yasushi, Saeki   +2 more
openaire   +1 more source

[Proteasome inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2010
The ubiquitin-proteasome pathway plays an important role in the regulation of cellular proteins with regard to cell cycle control, transcription, apoptosis, cell adhesion, angiogenesis and tumor growth. Proteasome inhibition is a novel approach to the treatment of solid tumors.
Masahiro, Yamamura   +2 more
openaire   +1 more source

PROTEASOME INHIBITOR

Nihon rinsho. Japanese journal of clinical medicine, 2014
The ubiquitin-proteasome system plays an essential role in degradation of eukaryotic intracellular protein, including cell cycle regulation, cell growth and proliferation, and survival. Cancer cells generally have higher level of proteasome activity compared with normal cells, suggesting proteasome inhibition could be therapeutic target in oncology ...
openaire   +3 more sources

Potent Inhibitors of Proteasome

Journal of Medicinal Chemistry, 1995
M, Iqbal   +7 more
openaire   +2 more sources

[Proteasome inhibitors].

La Revue de medecine interne, 2005
Proteasome is involved in cell cycle and apoptosis regulation. Its deregulation could participate to oncogenesis.Bortezomib is the first proteasome inhibitor to reach clinical development. Its main adverse events are asthenia, thrombocytopenia and cumulative neurotoxicity which can limits long term use.
openaire   +1 more source

Peptidomimetic proteasome inhibitors

2021
LIN GANG   +10 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy